Clopidogrel-induced systemic inflammatory response syndrome.
Clopidogrel bisulfate, a widely used inhibitor of platelet aggregation, is considered at least as safe as aspirin. We describe a patient who developed a systemic inflammatory response syndrome consisting of high fever, tachycardia, cellulitis-like rash, impaired liver function, and mild leukopenia after receiving clopidogrel before coronary angiography and stent implantation. The reaction resolved promptly after withdrawal of the drug and recurred shortly after a rechallenge dose was administered, thus making the diagnosis of a clopidogrel-induced reaction highly probable. Recognition of this clopidogrel-induced syndrome is extremely important, both for rapid discontinuation of the offending drug and for avoidance of unnecessary drug therapy or invasive procedures.
Department of Medicine E, Institute of Oncology, The Sheba Medical Center, Tel-Hashomer, Israel. ido.wolf@sheba.health.gov.il
Ido
I
Wolf
Meir
M
Mouallem
Shmuel
S
Rath
Zvi
Z
Farfel
D000077144:Clopidogrel; D017023:Coronary Angiography / Q000379:methods; D005260:Female; D006801:Humans; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D015607:Stents; D018746:Systemic Inflammatory Response Syndrome / Q000097:blood / Q000139:chemically induced*; D013988:Ticlopidine / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives
D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine